SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$85.32
+6.78%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$81.85
From 52W high−21.67%
Volume584436.00
Market cap$7.86B
P/E (TTM)—
P/S (TTM)86.9x
Div yield—
Key dataOct 19, 2026
Open
$81.85
From 52W high
−21.67%
Volume
584436.00
Market cap
$7.86B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.0x
P/E (TTM)
—
RSI (14)
48.9
MomentumView details →
1D Return
+6.78%
YTD Return
+161.15%
SummaryUpdated Jun 1, 2026
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a preclinical-stage biotechnology company founded in 2013 and headquartered in Waltham, Massachusetts. The company went public in April 2016 and underwent a significant strategic transformation in November 2023, when it changed its name from Aeglea BioTherapeutics to Spyre Therapeutics to reflect its new focus on inflammatory bowel disease treatments. This pivot marked a complete shift from the company's previous focus on rare genetic diseases to developing novel antibody therapies for patients suffering from inflammatory bowel disease.
Similar companies
Latest newsMore news →
Spyre Therapeutics, Inc. announced that it will present clinical and preclinical data at United European Gastroenterology Week 2026 in Barcelona.1d agoSpyre Therapeutics announced a common stock offering of 4.12 million shares at $85 per share, a 8.33% discount to the prior close, to raise about $350 million.13d agoSpyre Therapeutics, Inc. commenced an underwritten public offering of its common stock, with an expected 30-day underwriters' option for an additional 15% of the shares offered.14d ago